According to the terms of the deal, Samsung Biologics will provide additional capacity to GlaxoSmithKline signs manufacture deal with Samsung Biologics for large-scale manufacturing of biopharmaceutical products. This capacity may change based on GlaxoSmithKline signs manufacture deal with Samsung Biologics’s future needs and will support the company’s manufacturing network.
The eight-year agreement is valued at more than $231m and will initially see commercial production of Benlysta (belimumab). Technology transfer will begin this year with the first commercial supply expected in 2022.
In the future, the partnership will be expanded to add other speciality-care products.